Au0puggtpewncvjwkvix

Overactive bladder: Treatment

0.5 CME Credit hours

Course Title: Strategies to improve medical adherence and clinical management of overactive bladder - Treatment

Gain CME credit through our ACCME Accredited partner CME Outfitters


OAB is common in both women and men

Overactive bladder (OAB) is a common condition, with millions of people affected worldwide. It can affect work and social life and may even impair a person's ability to sleep. As the symptoms vary from one individual to another, treatment options are not the same for every person. There are a lot of factors to consider, by which managing OAB can be possible.

Many treatments are available for overactive bladder, including pelvic-muscle strengthening, behavioural therapies, medications, neuromodulation, and surgery. Guidelines suggest starting with less invasive therapies initially. The first line of therapy is non-pharmacological, which includes behavioural, dietary, and lifestyle therapies. Pharmacologic therapy is recommended as a second- line treatment. Third-line therapies consist of less-invasive surgical options and electrical stimulation therapies, including sacral neuromodulation and peripheral nerve stimulation (PTNS).

There is a significant influence of OAB on health-related quality of life. The importance of diagnoses and proper treatment cannot be overemphasized, especially in elderly patients. Practitioners need to be familiar with this condition. Basic knowledge about the diagnoses and treatment options can contribute greatly to the general health.

Here is a guide to help you deal with these cases.

Learning Objectives Of The Course
  1. Identify, discuss, and work with patients to overcome barriers to adherence to agree upon treatment plans for the management of overactive bladder (OAB)
  2. Initiate a communication dynamic that provides information on current and emerging treatments for overactive bladder (OAB) and the impact of medication adherence on patient health outcomes
Finance Support


Supported by an educational grant from Astellas Scientific and Medical Affairs, Inc.

Your Instructor


CME Outfitters
CME Outfitters

Since 2002, CME Outfitters has delivered innovative evidence-based educational activities to thousands of clinicians each year and offers expert accreditation and outcome services for non-accredited organizations. CME Outfitters focuses on delivering education to primary care, specialty audiences and community-based clinicians with strong expertise in neuroscience, gastroenterology, dermatology, rheumatology, immunology, virology, transplant, and cardiology. CME Outfitters is certified as a women’s business enterprise through the Women’s Business Enterprise National Council (WBENC), the nation’s largest third-party certifier of businesses owned and operated by women in the United States Click here to learn more


Sender Herschorn, BSc, MDCM, FRCSC

Professor; Division of Urology
University of Toronto
Head of the Urodynamics Laboratory; Sunnybrook Health Sciences Centre; Toronto, ON;Canada

Christopher Chapple, BSc, MD, FRCS (Urol), FEBU

Consultant Urological Surgeon
Royal Hallamshire Hospital
Honorary Senior Lecturer of Urology, University of Sheffield; Visiting Professor of Urology, Sheffield Hallam University; Chairman of the International Relations Office, European Association of Urology Sheffield, UK

Michael B. Chancellor, MD

Professor and Director of Neurourology
Oakland University, William Beaumont School of Medicine
Royal Oak, MI

Why take this course?
  1. Increase your knowledge and skills- this course will and help you identify cases of OAB, help you evaluate them and overcome barriers. Teach you strategies for medical adherence in such cases
  2. CME Certification
  3. Credit hours gained- 0.5 hrs
Target audience
  1. General Physicians
  2. Specialists
  3. Interns
  4. Residents
Course format


This course is provided in the form of a SCORM file. Upon completion of this course, please complete the post-test and the evaluation so as to apply for your CME certification. A passing rate of 75% is required to earn CME credit.

Basic requirement


Participant should have an MBBS degree

Accreditation and designation statement


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of CME Outfitters, LLC and CME Master. CME Outfitters, LLC is accredited by the ACCME to provide continuing medical education for physicians.


CME Outfitters, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Disclosure statement

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Faculty Disclosures:

Sender Herschorn, BSc, MDCM, FRCSC
Research/Grants: Allergan Inc.; Astellas Pharma Inc.; Pfizer Inc.
Speakers Bureau: Allergan Inc.;Astellas Pharma Inc.; Eli Lilly and Company; Pfizer Inc.
Consultant: Allergan Inc.; Astellas Pharma Inc.; Eli Lilly and Company; Pfizer Inc.

Christopher Chapple, BSc, MD, FRCS (Urol), FEBU
Research/Grants: Allergan Inc,; Astellas Pharma Inc.; Pfizer Inc.; Recordati S.p.A.
Speakers Bureau: Allergan Inc.; Astellas Pharma Inc.; Pfizer Inc.; Ranbaxy Laboratories Limited; Recordati S.p.A.
Consultant: Allergan Inc.; American Medical Systems, Inc.; Astellas Pharma Inc.; Eli Lilly and Company; Ono Pharmaceutical Co., Ltd; Pfizer Inc.; Recordati S.p.A.

Michael B. Chancellor, MD
Research Support: Allergan Inc.; Cook MyoSite, Inc.;Medtronic, Inc.
Consultant: Allergan Inc.;Astellas Pharma US, Inc.;Cook MyoSite, Inc.; Lipella Pharmaceuticals Inc.